Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Rheumatoid Arthritis – Current Treatment – Current Treatment: Physician Insights – Rheumatoid Arthritis (EU5)
Many established therapies are available to treat rheumatoid arthritis (RA). Tumor necrosis factor-alpha (TNF-alpha) inhibitors are the most widely used class of agents after conventional disease-…
Rheumatoid Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Rheumatoid Arthritis (US)
The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs) such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…
Rheumatoid Arthritis – Unmet Need – Unmet Need – TNFi-Refractory Rheumatoid Arthritis (US/EU)
Rheumatoid arthritis (RA) patients who are refractory to one or more tumor necrosis factor (TNF)-alpha inhibitors are generally prescribed a non-TNF-targeted therapy (e.g., Bristol Myers Squibb’s…
Rheumatoid Arthritis – Access & Reimbursement – Access and Reimbursement – Rheumatoid Arthritis (US)
The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, along with conventional treatments, makes the rheumatoid…
Rheumatoid Arthritis | Treatment Algorithms: Claims Data Analysis | US | 2024
The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs), such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…
Rheumatoid Arthritis – Geographic Focus: China – Rheumatoid Arthritis – China In-Depth (China)
Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has the highest number of RA patients in the world, and disease management is…
